Background: Tamoxifen citrate is a very prevalent drug marketed under several trade names
like Apo-Tamox, Nolvadex, Tamec, Tamizam, and Tamoplex. This molecule is approved by the FDA
for breast cancer treatment. Some studies have shown that tamoxifen has anti-tuberculosis and antiparasitic
activities. Like any drug, tamoxifen possesses side effects, more or less dangerous.
Aims: Basically, this work is a comparative study that aims to: primarily compare the antimicrobial and
antitumor activities of tamoxifen and a newly synthesized tamoxifen analog; and to determine the molecule
with lesser side effects.
Methods: Three groups of mice were injected with tamoxifen citrate and compound 2(1,1-bis[4-(3-
dimethylaminopropoxy)phenyl]-2-phenyl-but-1-ene dihydrochloride) at doses corresponding to C1
(1/10), C2 (1/50), and C3 (1/100) to compound 2 lethal dose (LD50 = 75 mg/kg) administered to adult
mice. A group of noninjected mice served as a study control.
Results: Experimental results suggest that compound 2 has better antitumor and antimicrobial activity
than tamoxifen citrate besides its lower toxicity effects.
Conclusion: The results obtained from the present study confirmed the antitumor and antimicrobial
effect of tamoxifen citrate and its hematological side effects. Compound 2 seems to be more effective
than tamoxifen citrate for antitumor and antimicrobial treatment while having less hematological side
effects and less disruption of the blood biochemical parameters. These findings encourage us to perform
further studies on compound 2 and test it for other therapeutic uses for which tamoxifen was found effective.